Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017589 · ClinicalTrials.gov registry record · Phase 2
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00017589 is a Phase 2 study that has completed, run by Genta Incorporated.
The verdict
NCT00017589, a Phase 2 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab ozogamicin in treating older patients who have relapsed acute myeloid leukemia.
Interventions
- DRUG gemtuzumab ozogamicin
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017589
The ClinicalTrials.gov registry entry for NCT00017589 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemtuzumab ozogamicin is the first listed.
NCT00017589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017589 about?
NCT00017589 is a clinical study titled "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PU...
What is the current status of trial NCT00017589?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00017589?
The interventions under investigation include: gemtuzumab ozogamicin (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017589?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.